In 2023, the Global Hospital Average Length of Stay for Hyperplasia of Prostate varied significantly across countries. The Czech Republic had the longest stay at 5.5 days, while Norway had the shortest at 1.6 days. Year-on-year, most countries experienced a reduction in stay duration, with Norway having the highest decrease of 5.29% and Lithuania seeing a decline of 3.09%. Iceland and the Czech Republic maintained a consistent stay length.
Looking ahead, advancements in medical practices, coupled with increasing healthcare efficiency, are expected to further decrease hospital stays. Emphasis on minimally invasive procedures and outpatient care models are likely to influence future trends globally.
Top countries in Hospital Average Length of Stay for Hyperplasia of Prostate by Country
| # | 8 Countries | Days | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Czech Republic | 5.5 | 2023 | 0% | 0% | View data |
| 2 | 2 Lithuania | 5.3 | 2023 | -1.85% | -3.09% | View data |
| 3 | 3 Hungary | 5.2 | 2023 | -1.89% | -1.82% | View data |
| 4 | 4 Austria | 4.8 | 2023 | -2.04% | -0.81% | View data |
| 5 | 5 Israel | 3.7 | 2023 | 0% | -1.05% | View data |
| 6 | 6 Iceland | 3.1 | 2023 | -3.13% | 0% | View data |
| 7 | 7 United Kingdom | 2.2 | 2023 | -4.35% | -1.73% | View data |
| 8 | 8 Norway | 1.6 | 2023 | -5.88% | -5.29% | View data |
